{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:31:17Z","timestamp":1793197877700,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006954","name":"Tufts Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jacc.2021.11.021","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T15:24:18Z","timestamp":1643037858000},"page":"390-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":377,"title":["Management of Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"79","author":[{"given":"Barry J.","family":"Maron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind Y.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick A.","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Rakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Towbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Dearani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan J.","family":"Rowin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark V.","family":"Sherrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.11.021_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.021_bib2","first-page":"376","article-title":"Global burden of hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Heart Fail"},{"issue":"Suppl IV","key":"10.1016\/j.jacc.2021.11.021_bib3","first-page":"1","article-title":"Idiopathic hypertrophic subaortic stenosis I. A description of the disease based upon an analysis of 64 patients","volume":"30","author":"Braunwald","year":"1964","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib4","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jacc.2021.11.021_bib5","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy","volume":"58","author":"Gersh","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib6","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy","volume":"76","author":"Ommen","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib9","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.amjcard.2016.02.044","article-title":"Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States","volume":"117","author":"Maron","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jama.281.7.650","article-title":"Clinical course of hypertrophic cardiomyopathy in a regional United States cohort","volume":"281","author":"Maron","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.11.021_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/CIRCRESAHA.119.315159","article-title":"Paradigm of sudden death prevention in hypertrophic cardiomyopathy","volume":"125","author":"Maron","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2021.11.021_bib12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCHEARTFAILURE.112.969626","article-title":"Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy:systematic review and meta-analysis","volume":"5","author":"Schinkel","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.11.021_bib13","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced ACC\/AHA strategy for prevention of sudden cardiac death in high risk patients with hypertrophic cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib14","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.117.027738","article-title":"Perspectives on the overall risks of living with hypertrophic cardiomyopathy","volume":"135","author":"Maron","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.hrthm.2021.01.019","article-title":"Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: 20 years with the implantable cardioverter-defibrillator","volume":"18","author":"Maron","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2021.11.021_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.298.4.405","article-title":"Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"298","author":"Maron","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.11.021_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamacardio.2015.0354","article-title":"How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice","volume":"1","author":"Maron","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib18","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.amjcard.2017.08.048","article-title":"Interaction of adverse disease-related pathways in hypertrophic cardiomyopathy","volume":"120","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ahj.2013.06.009","article-title":"Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications","volume":"166","author":"Vriesendorp","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2021.11.021_bib20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.amjcard.2012.04.030","article-title":"Cardiac transplantation in patients with hypertrophic cardiomyopathy","volume":"110","author":"Kato","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib22","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib23","first-page":"353","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"J\u00a0Am Coll Cardiol. Heart Fail"},{"key":"10.1016\/j.jacc.2021.11.021_bib24","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM200002103420601","article-title":"Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy","volume":"342","author":"Maron","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.021_bib26","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.119.040271","article-title":"Hypertrophic cardiomyopathy-related sudden cardiac death in young people in Ontario","volume":"140","author":"Weissler-Snir","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib27","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0735-1097(03)00941-0","article-title":"American College of Cardiology\/European Society of Cardiology clinical expert consensus document of hypertrophic cardiomyopathy","volume":"42","author":"Maron","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm:implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib30","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.112.136085","article-title":"Risk stratification and outcome of patients with hypertrophic cardiomyopathy\u00a0\u226560 years of age","volume":"127","author":"Maron","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.008123","article-title":"Long-term outcome in high-risk patients with hypertrophic cardiomyopathy after primary prevention defibrillator implants","volume":"13","author":"Rowin","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005820","article-title":"Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators","volume":"11","author":"Maron","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.hrthm.2020.07.026","article-title":"Back to the future: predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring","volume":"18","author":"Maron","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2021.11.021_bib35","article-title":"Impact of sex on clinical course and survival in the contemporary treatment era for hypertrophic cardiomyopathy","volume":"8","author":"Rowin","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.11.021_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamacardio.2019.4638","article-title":"Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy","volume":"5","author":"Eberly","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib37","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","article-title":"Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies","volume":"65","author":"Maron","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib38","first-page":"1019","article-title":"Evidence that subcutaneous implantable cardioverter-defibrillators are effective and reliable in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2020","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2021.11.021_bib39","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/europace\/euaa307","article-title":"Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: UK National Cohort Study","volume":"23","author":"Norrish","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2021.11.021_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.amjcard.2020.04.042","article-title":"Prediction and prevention of sudden death in young patients (< 20 years) with hypertrophic cardiomyopathy","volume":"128","author":"Rowin","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib41","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2013.01.037","article-title":"Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy","volume":"61","author":"Maron","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjcard.2019.04.002","article-title":"Impact of effective management strategies on patients with the most extreme phenotypic expression of hypertrophic cardiomyopathy","volume":"124","author":"Rowin","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A\u00a0validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib44","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jamacardio.2019.2861","article-title":"Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)","volume":"4","author":"Norrish","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib45","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/europace\/euz118","article-title":"A\u00a0validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"21","author":"Norrish","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2021.11.021_bib46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.115.017633","article-title":"Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/CIRCULATIONAHA.117.030437","article-title":"International external validation study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)","volume":"137","author":"O\u2019Mahony","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib48","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jcmg.2017.07.016","article-title":"Role of exercise testing in hypertrophic cardiomyopathy","volume":"10","author":"Rowin","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2021.11.021_bib49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/acs.2017.07.07","article-title":"Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy:the Tufts experience","volume":"6","author":"Rastegar","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2021.11.021_bib51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.112.000849","article-title":"Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib52","doi-asserted-by":"crossref","first-page":"364","DOI":"10.21037\/acs.2017.05.12","article-title":"Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience","volume":"6","author":"Vanderlaan","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2021.11.021_bib53","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.84.3.1188","article-title":"Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction","volume":"84","author":"Klues","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib54","first-page":"2289","article-title":"Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center","volume":"157","author":"Hodges","year":"2019","journal-title":"J\u00a0Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2021.11.021_bib55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamacardio.2019.4268","article-title":"Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy","volume":"5","author":"Fumagalli","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib56","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.amjcard.2020.02.013","article-title":"Distinctive hypertrophic cardiomyopathy anatomy and obstructive physiology in patients admitted with takotsubo syndrome","volume":"125","author":"Sherrid","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib57","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.11.021_bib58","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib59","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo controlled phase 3 tiral","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.11.021_bib60","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.athoracsur.2019.10.016","article-title":"Childhood hypertrophic obstructive cardiomyopathy and its relevant surgical outcomes","volume":"110","author":"Zhu","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2021.11.021_bib62","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib63","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/eurheartj\/ehm117","article-title":"Surgical septal myectomy decreases the risk of appropriate implantable cardioverter-defibrillator discharges in obstructive hypertrophic cardiomyopathy","volume":"28","author":"McLeod","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.021_bib64","article-title":"Outcomes in guideline-based class I indication versus earlier referral for surgical myectomy in hypertrophic cardiomyopathy","author":"Alashi","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.11.021_bib65","first-page":"630","article-title":"Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy","volume":"2","author":"Vriesendorp","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.11.021_bib66","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jacc.2015.07.069","article-title":"Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy","volume":"66","author":"Ferrazzi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib67","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1161\/CIRCULATIONAHA.118.035484","article-title":"Case for earlier surgical myectomy in patients with obstructive hypertrophic cardiomyopathy","volume":"138","author":"Maron","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib68","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2016.01.071","article-title":"The mitral valve in obstructive hypertrophic cardiomyopathy:a test in context","volume":"67","author":"Sherrid","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib69","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2018.06.055","article-title":"Clinical spectrum and management implications of left ventricular outflow obstruction with mild ventricular septal thickness in hypertrophic cardiomyopathy","volume":"122","author":"Rowin","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.21037\/acs.2017.07.03","article-title":"Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience","volume":"6","author":"Kotkar","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2021.11.021_bib71","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.amjcard.2014.07.075","article-title":"Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010])","volume":"114","author":"Panaich","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib72","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/eurheartj\/ehs064","article-title":"A\u00a0contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy","volume":"33","author":"Iacovoni","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.021_bib73","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.amjmed.2017.12.031","article-title":"Clinical profile of nonresponders to surgical myectomy with obstructive hypertrophic cardiomyopathy","volume":"131","author":"Wells","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2021.11.021_bib74","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2019.09.029","article-title":"Efficacy of combined Cox-Maze IV and ventricular septal myectomy for treatment of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy","volume":"125","author":"Boll","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jtcvs.2019.03.088","article-title":"Apical myectomy for patients with hypertrophic cardiomyopathy advanced heart failure","volume":"159","author":"Nugyen","year":"2020","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2021.11.021_bib76","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1161\/01.CIR.99.22.2927","article-title":"Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized double-blind crossover study. (M-PATHY)","volume":"99","author":"Maron","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib77","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003689","article-title":"Mechanism of progressive heart failure and significance of pulmonary hypertension in obstructive hypertrophic cardiomyopathy","volume":"10","author":"Covella","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.11.021_bib78","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2019.05.053","article-title":"Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy","volume":"74","author":"Cui","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib79","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2017.06.011","article-title":"Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of balance","volume":"70","author":"Sorajja","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib80","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.jacc.2011.06.073","article-title":"Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: a multicenter North American registry","volume":"58","author":"Nagueh","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib81","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","article-title":"Survival after alcohol septal\u00a0ablation in patients with hypertrophic cardiomyopathy","volume":"72","author":"Batzner","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib82","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1161\/CIRCULATIONAHA.114.011580","article-title":"Surgical septal myectomy versus alcohol septal ablation: assessing status of the controversy in 2014","volume":"130","author":"Maron","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib83","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib84","first-page":"1394","article-title":"Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy","volume":"113","author":"Olivotto","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib85","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIRCHEARTFAILURE.114.001435","article-title":"Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant","volume":"7","author":"Rowin","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.11.021_bib86","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacc.2017.11.040","article-title":"Cardiac resynchronization therapy for end-stage hypertrophic cardiomyopathy: the need for disease-specific criteria","volume":"71","author":"Cappelli","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib87","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.amjcard.2021.04.021","article-title":"Usefulness of global longitudinal strain to predict heart failure progression in patients with nonobstructive hypertrophic cardiomyopathy","volume":"151","author":"Rowin","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib88","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.amjcard.2015.11.013","article-title":"What do patients with hypertrophic cardiomyopathy die from?","volume":"117","author":"Maron","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib89","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCHEARTFAILURE.109.922872","article-title":"Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy","volume":"3","author":"Maron","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.11.021_bib90","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy:prevalence, clinical correlations, and mortality in a large high-risk population","volume":"3","author":"Siontis","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.11.021_bib91","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib92","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/heartjnl-2016-309672","article-title":"Predictors of atrial fibrillation in hypertrophic cardiomyopathy","volume":"103","author":"Guttman","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2021.11.021_bib93","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.009796","article-title":"Development and validation of a clinical predictive model for identifying hypertrophic cardiomyopathy patients at risk for atrial fibrillation: The HCM-AF score","volume":"14","author":"Carrick","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib94","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.amjcard.2017.02.040","article-title":"Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy","volume":"119","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib95","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamacardio.2019.4534","article-title":"Mortality among referral patients with hypertrophic cardiomyopathy vs. the general European population","volume":"5","author":"Lorenzini","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib96","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamacardio.2018.0789","article-title":"Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events","volume":"3","author":"Maurizi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib97","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.117.032838","article-title":"Association between race and clinical profile of patients referred for hypertrophic cardiomyopathy","volume":"137","author":"Wells","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.021_bib98","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.amjcard.2020.11.035","article-title":"Low risk of hypertrophic cardiomyopathy implemented in a non-referral and regional community-based center","volume":"142","author":"Shirani","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib99","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.amjcard.2015.04.027","article-title":"Importance and feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in India","volume":"116","author":"Maron","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021095","article-title":"Cardiovascular diseases that have emerged from the darkness","volume":"10","author":"Maron","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.jacc.2021.11.021_bib101","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.amjcard.2004.01.057","article-title":"Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy","volume":"93","author":"Jayatilleke","year":"2004","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2021.11.021_bib102","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/hrt.2006.090290","article-title":"Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy","volume":"93","author":"Woo","year":"2007","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.jacc.2021.11.021_bib103","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1540-8159.2008.01174.x","article-title":"Circadian rhythm of appropriate implantable cardioverter defibrillator discharges in patients with hypertrophic cardiomyopathy","volume":"31","author":"Kiernan","year":"2008","journal-title":"Pacing Clin Electrophysiol"},{"issue":"9","key":"10.1016\/j.jacc.2021.11.021_bib104","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/hrt.2008.150656","article-title":"Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy","volume":"95","author":"Lin","year":"2009","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.jacc.2021.11.021_bib105","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2010.06.077","article-title":"Role of family history of sudden death in risk stratification and prevention of sudden death with\u00a0implantable defibrillators in hypertrophic cardiomyopathy","volume":"106","author":"Bos","year":"2010","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2021.11.021_bib106","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1540-8167.2009.01716.x","article-title":"Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up","volume":"21","author":"Syska","year":"2010","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2021.11.021_bib107","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/AC.65.5.2056238","article-title":"Incidence of adequate ICD interventions in patients with hypertrophic cardiomyopathy supposed to be at high risk for sudden\u00a0cardiac death","volume":"65","author":"Prinz","year":"2010","journal-title":"Acta Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2021.11.021_bib108","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2459\/JCM.0000000000000333","article-title":"Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy","volume":"17","author":"Konstantinou","year":"2016","journal-title":"J\u00a0Cardiovasc Med (Hagerstown)"},{"issue":"1","key":"10.1016\/j.jacc.2021.11.021_bib109","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.hrthm.2020.08.009","article-title":"Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-are there predictors of appropriate therapy?","volume":"18","author":"Weissler-Snir","year":"2021","journal-title":"Heart Rhythm"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721082103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721082103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:47:34Z","timestamp":1760017654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721082103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0735109721082103"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.11.021","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.12.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}